Section of Bone Marrow Transplant & Leukemia

Medicine & Life Sciences

1. Acute Myeloid Leukemia 86%
2. Acute Promyelocytic Leukemia 9%
3. Allogeneic Cells 39%
4. Autologous Transplantation 15%
5. axicabtagene ciloleucel 13%
6. Azacitidine 7%
7. B-Cell Lymphoma 10%
8. B-Lymphocytes 12%
9. Biomarkers 8%
10. Blood Cells 10%
11. Bone Marrow 47%
12. Bone Marrow Cells 7%
13. Bone Marrow Transplantation 8%
14. Bortezomib 16%
15. Breast Neoplasms 17%
16. carfilzomib 20%
17. Carmustine 7%
18. Cell Line 9%
19. Cell Transplantation 63%
20. Cell- and Tissue-Based Therapy 11%
21. Chimeric Antigen Receptors 20%
22. Clinical Trials 9%
23. Clone Cells 7%
24. Confidence Intervals 14%
25. Cyclophosphamide 17%
26. Cytarabine 14%
27. Cytogenetics 11%
28. Cytokine Release Syndrome 7%
29. Cytokines 10%
30. Decitabine 11%
31. Dexamethasone 11%
32. Drug Therapy 21%
33. Follicular Lymphoma 8%
34. GATA2 Deficiency 12%
35. Genes 22%
36. Genome 23%
37. Genomics 7%
38. Graft vs Host Disease 50%
39. Granulocyte Colony-Stimulating Factor 43%
40. Granulocyte Colony-Stimulating Factor Receptors 13%
41. Granulocyte-Macrophage Colony-Stimulating Factor 8%
42. Guidelines 10%
43. Hematologic Neoplasms 15%
44. Hematopoiesis 10%
45. Hematopoietic Stem Cell Mobilization 22%
46. Hematopoietic Stem Cell Transplantation 21%
47. Hematopoietic Stem Cells 44%
48. High-Throughput Nucleotide Sequencing 10%
49. Hodgkin Disease 8%
50. Homologous Transplantation 17%
51. Immunotherapy 10%
52. INCB018424 10%
53. Intercellular Signaling Peptides and Proteins 7%
54. Lenalidomide 21%
55. Leukemia 31%
56. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10%
57. Lymphoma 11%
58. Lymphoma, Large B-Cell, Diffuse 11%
59. Mantle-Cell Lymphoma 7%
60. Melphalan 8%
61. Mortality 12%
62. Multicenter Studies 7%
63. Multiple Myeloma 100%
64. Mutation 32%
65. Myelodysplastic Syndromes 31%
66. Myeloid Cells 8%
67. Natural Killer Cells 8%
68. Neoplasms 46%
69. Neutropenia 7%
70. Neutropenia, Severe Congenital, Autosomal Recessive 3 14%
71. Neutrophils 14%
72. Non-Hodgkin's Lymphoma 17%
73. Peripheral Blood Stem Cell Transplantation 7%
74. Peripheral Blood Stem Cells 11%
75. Placebos 7%
76. plerixafor octahydrochloride 28%
77. Population 7%
78. Practice Guidelines 7%
79. Precursor Cell Lymphoblastic Leukemia-Lymphoma 15%
80. Progression-Free Survival 18%
81. Prostatic Neoplasms 7%
82. Proteasome Inhibitors 9%
83. Protein-Tyrosine Kinases 9%
84. Proteins 8%
85. Recurrence 20%
86. Rituximab 8%
87. RNA Sequence Analysis 8%
88. Safety 13%
89. Stem Cell Transplantation 25%
90. Stem Cells 30%
91. Survival 36%
92. T-Lymphocytes 25%
93. Therapeutics 33%
94. Tissue Donors 21%
95. Transcriptome 8%
96. Transplantation 21%
97. Transplants 42%
98. Unrelated Donors 15%
99. Whole Genome Sequencing 9%
100. Whole-Body Irradiation 8%